{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:41:23Z","timestamp":1787499683876,"version":"build-2736575974"},"reference-count":42,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T00:00:00Z","timestamp":1733961600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background &amp; aims<\/jats:title>\n                    <jats:p>Gait disturbances are commonly observed in patients with neurodegenerative disorders, including Alzheimer\u2019s disease, Parkinson\u2019s disease, and higher-level gait disorders, which are associated with cholinergic deficits. We conducted a systematic review and meta-analysis to investigate the effects of rivastigmine on improvement in gait.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A comprehensive literature search was conducted using Medical Subject Heading (MeSH) terms and text keywords related to gait and falls after rivastigmine treatment for neurodegenerative disorders. The intervention (rivastigmine), comparison (control or no treatment), and outcomes of improvement in gait speed and fall were assessed from database inception to April 2024. References and collected data were meticulously reviewed to ensure the integrity of the included studies. Standardized mean differences (SMDs) and Hedges\u2019g, along with their 95% confidence intervals (Cls), were calculated for gait speed and number of falls.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 222 articles were identified during the initial search across different electronic databases, 50 including PubMed (n = 23), Cochrane (n = 19), Embase (n = 139), Scopus (n = 38), and a manual search (n = 3). Finally, we conducted a systematic review and meta-analysis focusing on the final four studies, encompassing 286 participants. The pooled SMD for the overall gait speed without a comparison group was 0.761 (95% CI: \u22121.165 to 2.688), indicating no significant improvement in gait speed. For the overall number of falls between the rivastigmine treatment and control groups, the pooled SMD was \u22120.366 (95% CI: \u22120.650 to \u22120.083). A statistically significant reduction in the number of falls was observed in the rivastigmine group than in the control group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Rivastigmine treatment in patients with neurodegenerative disorders tend to improve gait speed and significantly reduces fall incidence. Given the limited efficacy of current treatments for gait disturbances and falls, dual cholinesterase inhibitors like rivastigmine could be a promising therapeutic option.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0310900","type":"journal-article","created":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T13:24:02Z","timestamp":1734009842000},"page":"e0310900","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effects of rivastigmine on gait in patients with neurodegenerative disorders: A systematic review and meta-analysis"],"prefix":"10.1371","volume":"19","author":[{"given":"Sung Ryul","family":"Shim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1230-9307","authenticated-orcid":true,"given":"Jong-Yeup","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyum-Yil","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieun","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yungjin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0554-0906","authenticated-orcid":true,"given":"Seon-Min","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,12,12]]},"reference":[{"issue":"8","key":"pone.0310900.ref001","doi-asserted-by":"crossref","first-page":"738","DOI":"10.2174\/1389201015666140827104918","article-title":"Biochemical, Biomedical and Metabolic Aspects of Imidazole-Containing Dipeptides with the Inherent Complexity to Neurodegenerative Diseases and Various States of Mental Well-Being: A Challenging Correction and Neurotherapeutic Pharmaceutical Biotechnology for Treating Cognitive Deficits, Depression and Intellectual Disabilities","volume":"15","author":"MA Babizhayev","year":"2014","journal-title":"Curr Pharm Biotechnol"},{"issue":"3","key":"pone.0310900.ref002","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/mds.21720","article-title":"The role of executive function and attention in gait","volume":"23","author":"G Yogev-Seligmann","year":"2008","journal-title":"Mov Disord"},{"issue":"20","key":"pone.0310900.ref003","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1212\/WNL.0b013e3181c1ded6","article-title":"History of falls in Parkinson disease is associated with reduced cholinergic activity","volume":"73","author":"NI Bohnen","year":"2009","journal-title":"Neurology"},{"issue":"Pt 3","key":"pone.0310900.ref004","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1093\/brain\/aws373","article-title":"Motor cortex and gait in mild cognitive impairment: a magnetic resonance spectroscopy and volumetric imaging study","volume":"136","author":"C Annweiler","year":"2013","journal-title":"Brain"},{"issue":"3","key":"pone.0310900.ref005","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1474-4422(15)00389-0","article-title":"Rivastigmine for gait stability in patients with Parkinson\u2019s disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"15","author":"EJ Henderson","year":"2016","journal-title":"Lancet Neurol"},{"issue":"5","key":"pone.0310900.ref006","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1111\/j.1532-5415.2008.01657.x","article-title":"Galantamine improves gait performance in patients with Alzheimer\u2019s disease","volume":"56","author":"F Assal","year":"2008","journal-title":"J Am Geriatr Soc"},{"issue":"14","key":"pone.0310900.ref007","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1212\/WNL.0b013e3181f6128c","article-title":"Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease","volume":"75","author":"KA Chung","year":"2010","journal-title":"Neurology"},{"issue":"7","key":"pone.0310900.ref008","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1136\/jnnp-2014-308764","article-title":"Cholinesterase inhibitors for Parkinson\u2019s disease: a systematic review and meta-analysis","volume":"86","author":"G Pagano","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"pone.0310900.ref009","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41531-021-00251-1","article-title":"Cholinesterase inhibitors for gait, balance, and fall in Parkinson disease: a meta-analysis","volume":"7","author":"JH Chen","year":"2021","journal-title":"NPJ Parkinsons Dis"},{"issue":"7","key":"pone.0310900.ref010","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"D Moher","year":"2009","journal-title":"PLoS Med"},{"issue":"1","key":"pone.0310900.ref011","doi-asserted-by":"crossref","first-page":"123","DOI":"10.21032\/jhis.2016.41.1.123","article-title":"Intervention Meta-Analysis Using STATA Software","volume":"41","author":"S-R Shim","year":"2016","journal-title":"J Health Info Stat"},{"key":"pone.0310900.ref012","doi-asserted-by":"crossref","first-page":"e2019008","DOI":"10.4178\/epih.e2019008","article-title":"Intervention meta-analysis: application and practice using R software","volume":"41","author":"SR Shim","year":"2019","journal-title":"Epidemiol Health"},{"issue":"1","key":"pone.0310900.ref013","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1164","article-title":"Methods to estimate the between-study variance and its uncertainty in meta-analysis","volume":"7","author":"AA Veroniki","year":"2016","journal-title":"Res Synth Methods"},{"issue":"4","key":"pone.0310900.ref014","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"CB Begg","year":"1994","journal-title":"Biometrics"},{"issue":"7124","key":"pone.0310900.ref015","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1136\/bmj.316.7124.61","article-title":"Bias in location and selection of studies","volume":"316","author":"M Egger","year":"1998","journal-title":"BMJ"},{"key":"pone.0310900.ref016","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"JAC Sterne","year":"2019","journal-title":"Bmj"},{"key":"pone.0310900.ref017","unstructured":"Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. Edited by: Higgins JPT GShwc-ho."},{"issue":"2","key":"pone.0310900.ref018","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s40268-014-0038-8","article-title":"Effect of rivastigmine on mobility of patients with higher-level gait disorder: a pilot exploratory study","volume":"14","author":"T Gurevich","year":"2014","journal-title":"Drugs R D"},{"issue":"1\u20132","key":"pone.0310900.ref019","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1159\/000438824","article-title":"Impact of Rivastigmine on Cognitive Dysfunction and Falling in Parkinson\u2019s Disease Patients","volume":"74","author":"Z Li","year":"2015","journal-title":"Eur Neurol"},{"issue":"1","key":"pone.0310900.ref020","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12883-021-02098-8","article-title":"Rivastigmine improves dual-task gait velocity in patients with Alzheimer\u2019s disease","volume":"21","author":"H Shimura","year":"2021","journal-title":"BMC Neurol"},{"key":"pone.0310900.ref021","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.neubiorev.2018.12.017","article-title":"The neural correlates of discrete gait characteristics in ageing: A structured review","volume":"100","author":"J Wilson","year":"2019","journal-title":"Neurosci Biobehav Rev"},{"key":"pone.0310900.ref022","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.neubiorev.2016.02.012","article-title":"Gait and cognition: Mapping the global and discrete relationships in ageing and neurodegenerative disease","volume":"64","author":"R Morris","year":"2016","journal-title":"Neurosci Biobehav Rev"},{"key":"pone.0310900.ref023","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.parkreldis.2019.02.017","article-title":"Overview of the cholinergic contribution to gait, balance and falls in Parkinson\u2019s disease","volume":"63","author":"R Morris","year":"2019","journal-title":"Parkinsonism Relat Disord"},{"issue":"4","key":"pone.0310900.ref024","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/0306-4522(83)90108-2","article-title":"Central cholinergic pathways in the rat: an overview based on an alternative nomenclature (Ch1-Ch6)","volume":"10","author":"MM Mesulam","year":"1983","journal-title":"Neuroscience"},{"issue":"1","key":"pone.0310900.ref025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0966-6362(01)00156-4","article-title":"Attention and the control of posture and gait: a review of an emerging area of research","volume":"16","author":"M Woollacott","year":"2002","journal-title":"Gait Posture"},{"issue":"1","key":"pone.0310900.ref026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0301-0082(95)00013-L","article-title":"The pedunculopontine tegmental nucleus: where the striatum meets the reticular formation","volume":"47","author":"WL Inglis","year":"1995","journal-title":"Prog Neurobiol"},{"issue":"1","key":"pone.0310900.ref027","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/syn.10165","article-title":"In vivo muscarinic 2 receptor imaging in cognitively normal young and older volunteers","volume":"48","author":"TA Podruchny","year":"2003","journal-title":"Synapse"},{"key":"pone.0310900.ref028","doi-asserted-by":"crossref","first-page":"697","DOI":"10.2147\/CIA.S129145","article-title":"Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson\u2019s disease dementia","volume":"12","author":"N Kandiah","year":"2017","journal-title":"Clin Interv Aging"},{"issue":"5","key":"pone.0310900.ref029","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/jnc.13899","article-title":"ExPPNing how acetylcholine improves gait in Parkinson\u2019s disease: An Editorial Highlight for \u2019Deletion of the Vesicular Acetylcholine Transporter from Pedunculopontine\/laterodorsal tegmental neurons modifies gait\u2019","volume":"140","author":"B. Falkenburger","year":"2017","journal-title":"J Neurochem"},{"key":"pone.0310900.ref030","doi-asserted-by":"crossref","first-page":"101752","DOI":"10.1016\/j.jchemneu.2020.101752","article-title":"Advancement in the modelling and therapeutics of Parkinson\u2019s disease","volume":"104","author":"SN Rai","year":"2020","journal-title":"J Chem Neuroanat"},{"issue":"3","key":"pone.0310900.ref031","doi-asserted-by":"crossref","DOI":"10.3390\/diseases11030089","article-title":"WNT-beta Catenin Signaling as a Potential Therapeutic Target for Neurodegenerative Diseases: Current Status and Future Perspective","volume":"11","author":"K Ramakrishna","year":"2023","journal-title":"Diseases"},{"key":"pone.0310900.ref032","first-page":"33","article-title":"A Comprehensive Review and Androgen Deprivation Therapy and Its Impact on Alzheimer\u2019s Disease Risk in Older Men with Prostate Cancer","volume":"14","author":"M Singh","year":"2024","journal-title":"Degener Neurol Neuromuscul Dis"},{"issue":"1","key":"pone.0310900.ref033","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1017\/S1461145705005833","article-title":"Targeting acetylcholinesterase and butyrylcholinesterase in dementia","volume":"9","author":"RM Lane","year":"2006","journal-title":"Int J Neuropsychopharmacol"},{"issue":"3","key":"pone.0310900.ref034","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1185\/03007990152673800","article-title":"A new therapeutic target in Alzheimer\u2019s disease treatment: attention to butyrylcholinesterase","volume":"17","author":"NH Greig","year":"2001","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"pone.0310900.ref035","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0306-4522(01)00613-3","article-title":"Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine","volume":"110","author":"MM Mesulam","year":"2002","journal-title":"Neuroscience"},{"issue":"1","key":"pone.0310900.ref036","doi-asserted-by":"crossref","first-page":"79","DOI":"10.18433\/J3MK59","article-title":"Effects of rivastigmine and donepezil on brain acetylcholine levels in acetylcholinesterase-deficient mice","volume":"12","author":"RS Naik","year":"2009","journal-title":"J Pharm Pharm Sci"},{"issue":"1","key":"pone.0310900.ref037","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jphys.2022.11.005","article-title":"Normal gait speed varies by age and sex but not by geographical region: a systematic review","volume":"69","author":"AW Andrews","year":"2023","journal-title":"J Physiother"},{"key":"pone.0310900.ref038","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3389\/fnhum.2017.00353","article-title":"Guidelines for Assessment of Gait and Reference Values for Spatiotemporal Gait Parameters in Older Adults: The Biomathics and Canadian Gait Consortiums Initiative","volume":"11","author":"O Beauchet","year":"2017","journal-title":"Front Hum Neurosci"},{"issue":"19","key":"pone.0310900.ref039","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1080\/09638288.2017.1329357","article-title":"Longitudinal falls data in Parkinson\u2019s disease: feasibility of fall diaries and effect of attrition","volume":"40","author":"H Hunter","year":"2018","journal-title":"Disabil Rehabil"},{"issue":"11","key":"pone.0310900.ref040","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1007\/s00415-017-8620-y","article-title":"Natural history of falls in an incident cohort of Parkinson\u2019s disease: early evolution, risk and protective features","volume":"264","author":"S Lord","year":"2017","journal-title":"J Neurol"},{"key":"pone.0310900.ref041","first-page":"47","article-title":"Review of Pharmacotherapeutic Targets in Alzheimer\u2019s Disease and Its Management Using Traditional Medicinal Plants","volume":"14","author":"PN Tripathi","year":"2024","journal-title":"Degener Neurol Neuromuscul Dis"},{"key":"pone.0310900.ref042","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchemneu.2016.11.009","article-title":"Mucuna pruriens reduces inducible nitric oxide synthase expression in Parkinsonian mice model","volume":"80","author":"SK Yadav","year":"2017","journal-title":"J Chem Neuroanat"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0310900","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T13:24:33Z","timestamp":1734009873000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0310900"}},"subtitle":[],"editor":[{"given":"Ghulam Md","family":"Ashraf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,12,12]]},"references-count":42,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0310900","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,12]]}}}